08.27.13
Dublin, Ireland-based Covidien plc has opened a new facility dubbed the Covidien Center of Innovation (CCI) Korea in Seoul. It is the company’s first research and development (R&D) and training and education center in Korea.
Covidien invested $21 million into the center over the past three years. CCI Korea is a high-tech medical training center focused on raising awareness of various disease states and bringing Covidien’s product line closer to its Korean market.
“It is our responsibility and honor to help advance physician capabilities and uncover opportunities for locally tailored solutions to increase access to the best patient care,” said Brian D. King, president of Covidien’s emerging markets business. “Korea is a key market in our global strategy, and this investment is a reflection of our commitment to partnering with Korean healthcare professionals.”
The 6,000-square-foot center has a surgical lab with 11 operating stations; an intensive care unit (ICU) lab with two ICU stations and a human patient simulator; and an auditorium with seating capacity for 112 people that has 3-D/high-definition display technology and a state-of-the-art, optimized sound system to provide an immersive and experiential training environment.
“There is an increased expectation and focus on medical technology to help improve patient outcomes,” said Peter Kim, managing director of Covidien’s Korea business. “With the opening of CCI Korea, Covidien can further advance healthcare professional capabilities and enhance collaboration activities between R&D professionals, academic institutions and healthcare professionals to create access to improved standards of care.”
Earlier this year, Covidien signed two memorandums of understanding with the Korean Surgical Society and the Korean Society for Thoracic & Cardiovascular Surgery. In accordance with these agreements, all healthcare professionals affiliated with these two societies will experience CCI Korea as part of their mandatory certification programs. According to company officials, Covidien will continue to collaborate with Korean medical societies for training programs and new product development at CCI Korea, with a focus on promoting national health and advancing medical technology in the country.
Covidien makes a range of medical and surgical devices. The company’s U.S. headquarters are in Mansfield, Mass.
Covidien invested $21 million into the center over the past three years. CCI Korea is a high-tech medical training center focused on raising awareness of various disease states and bringing Covidien’s product line closer to its Korean market.
“It is our responsibility and honor to help advance physician capabilities and uncover opportunities for locally tailored solutions to increase access to the best patient care,” said Brian D. King, president of Covidien’s emerging markets business. “Korea is a key market in our global strategy, and this investment is a reflection of our commitment to partnering with Korean healthcare professionals.”
The 6,000-square-foot center has a surgical lab with 11 operating stations; an intensive care unit (ICU) lab with two ICU stations and a human patient simulator; and an auditorium with seating capacity for 112 people that has 3-D/high-definition display technology and a state-of-the-art, optimized sound system to provide an immersive and experiential training environment.
“There is an increased expectation and focus on medical technology to help improve patient outcomes,” said Peter Kim, managing director of Covidien’s Korea business. “With the opening of CCI Korea, Covidien can further advance healthcare professional capabilities and enhance collaboration activities between R&D professionals, academic institutions and healthcare professionals to create access to improved standards of care.”
Earlier this year, Covidien signed two memorandums of understanding with the Korean Surgical Society and the Korean Society for Thoracic & Cardiovascular Surgery. In accordance with these agreements, all healthcare professionals affiliated with these two societies will experience CCI Korea as part of their mandatory certification programs. According to company officials, Covidien will continue to collaborate with Korean medical societies for training programs and new product development at CCI Korea, with a focus on promoting national health and advancing medical technology in the country.
Covidien makes a range of medical and surgical devices. The company’s U.S. headquarters are in Mansfield, Mass.